Oxitocina Hikma (Oxytocin)

Oxitocina Hikma is a uterotonic peptide that acts on the uterine smooth muscle to promote contraction.

• Induction of labor: facilitates cervical dilation and progression of active labor.
• Management of postpartum hemorrhage: supports uterine tone to reduce bleeding after delivery.
• Induction of abortion: promotes uterine evacuation in early pregnancy termination procedures.

• Oxytocin binds to specific oxytocin receptors on uterine smooth‑muscle cells, activating a phosphoinositide signaling cascade that raises intracellular calcium levels. The increased calcium triggers muscle contraction, leading to coordinated uterine tightening that assists in labor progression and hemorrhage control.

Oxytocin may cause a range of adverse reactions, most of which are dose‑dependent and related to its uterotonic activity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Headache: transient headache during infusion.
• Flushing: temporary facial redness.
• Uterine hyperstimulation: excessive contractions.
• Hypotension: drop in blood pressure, especially with rapid administration.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heart rhythm.
• Myocardial ischemia: reduced blood flow to heart muscle.
• Water intoxication: hyponatremia from excess fluid retention.
• Severe allergic reaction: anaphylaxis or anaphylactoid response.
• Uterine rupture: tearing of the uterine wall, particularly in a scarred uterus.

When using Oxitocina Hikma, clinicians should observe several safety measures to minimize risk.

• Monitor uterine activity: continuous fetal and uterine monitoring is essential.
• Assess maternal cardiovascular status: watch for hypotension and tachycardia.
• Avoid rapid bolus injection: administer slowly to reduce hyperstimulation.
• Use caution in scarred uterus: increased risk of rupture.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Oxytocin can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• General anesthetics: may potentiate uterine relaxation, reducing oxytocin effectiveness.
• Magnesium sulfate: can diminish uterine contractility and increase risk of hyperstimulation.

Moderate Interactions (Monitor Closely)

• Antihypertensives: may exacerbate hypotensive effects of oxyt4.
• Beta‑adrenergic blockers.
• Vasopressors.
• Calcium channel blockers.
• Diuretics.
• Prostaglandin analogues.
• NSAIDs.
• Sedatives.
• Opioid analgesics.
• Anticholinergics.
• Antidepressants.
• Anticonvulsants.
• Herbal supplements.
• Vacc